Business Description
Edgewise Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US28036F1057
Total Employee Number:
127Description
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 128.33 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -11.5 | |||||
3-Year EPS without NRI Growth Rate | -9 | |||||
3-Year FCF Growth Rate | -8.8 | |||||
3-Year Book Growth Rate | -3.6 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.37 | |||||
9-Day RSI | 40.98 | |||||
14-Day RSI | 46.42 | |||||
3-1 Month Momentum % | 5.99 | |||||
6-1 Month Momentum % | 33.22 | |||||
12-1 Month Momentum % | 162.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 16.24 | |||||
Quick Ratio | 16.24 | |||||
Cash Ratio | 15.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -18.9 | |||||
Shareholder Yield % | 0.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -37.76 | |||||
ROA % | -35.89 | |||||
ROIC % | -1086.49 | |||||
3-Year ROIIC % | -1511.97 | |||||
ROC (Joel Greenblatt) % | -2391.62 | |||||
ROCE % | -41.68 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 32.57 | |||||
PB Ratio | 10.08 | |||||
Price-to-Tangible-Book | 10.08 | |||||
EV-to-EBIT | -18.73 | |||||
EV-to-Forward-EBIT | -13.44 | |||||
EV-to-EBITDA | -18.93 | |||||
EV-to-Forward-EBITDA | -13.44 | |||||
EV-to-Forward-Revenue | 38.19 | |||||
EV-to-FCF | -25.81 | |||||
| Price-to-Net-Current-Asset-Value | 10.28 | |||||
| Price-to-Net-Cash | 10.54 | |||||
Earnings Yield (Greenblatt) % | -5.34 | |||||
FCF Yield % | -3.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EWTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Edgewise Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.85 | ||
| Beta | 0.6767 | ||
| 3-Year Sharpe Ratio | 0.99 | ||
| 3-Year Sortino Ratio | 2.81 | ||
| Volatility % | 44.32 | ||
| 14-Day RSI | 46.42 | ||
| 14-Day ATR ($) | 2.214249 | ||
| 20-Day SMA ($) | 43.67875 | ||
| 12-1 Month Momentum % | 162.25 | ||
| 52-Week Range ($) | 13.685 - 48.4 | ||
| Shares Outstanding (Mil) | 108.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Edgewise Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Edgewise Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-26 | In 175 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 175 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 63 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 44.99 (+0.31%) | ||
| 12-Week Phase 2 CIRRUS-HCM Trial Top-line Data Event | 2026-06-16 08:30 | 35.21 (-0.65%) | ||
| General meeting for 2025 | 2026-06-04 10:00 | 36.21 (-4.79%) | ||
| RBC Capital Markets Global Healthcare Conference | 2026-05-20 10:00 | 31.43 (-0.29%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 36.99 (-2.50%) | ||
| Leerink Global Healthcare Conference | 2026-03-11 13:40 | 29.30 (+2.23%) | ||
| Annual report for 2025 | 2026-02-26 | 30.12 (-2.84%) |
Show
Entries
Edgewise Therapeutics Inc Frequently Asked Questions
What is Edgewise Therapeutics Inc(EWTX)'s stock price today?
The current price of EWTX is $41.94. The 52 week high of EWTX is $48.40 and 52 week low is $13.69.
When is next earnings date of Edgewise Therapeutics Inc(EWTX)?
The next earnings date of Edgewise Therapeutics Inc(EWTX) is 2026-11-06 Est..
Does Edgewise Therapeutics Inc(EWTX) pay dividends? If so, how much?
Edgewise Therapeutics Inc(EWTX) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers